Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder (“MDD”) on track for Q4 20261,2 HLP004 Program progressing with Phase 2 monoth
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.